ID   HCK_HUMAN               Reviewed;         526 AA.
AC   P08631; A8K1I1; B4DQB6; E1P5M2; Q29RX1; Q2VPE2; Q504R5; Q5T7K1;
AC   Q5T7K2; Q96CC0; Q9H5Y5; Q9NUA4; Q9UMJ5;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 5.
DT   10-MAY-2017, entry version 223.
DE   RecName: Full=Tyrosine-protein kinase HCK;
DE            EC=2.7.10.2;
DE   AltName: Full=Hematopoietic cell kinase;
DE   AltName: Full=Hemopoietic cell kinase;
DE   AltName: Full=p59-HCK/p60-HCK;
DE   AltName: Full=p59Hck;
DE   AltName: Full=p61Hck;
GN   Name=HCK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3496523; DOI=10.1128/MCB.7.6.2267;
RA   Quintrell N., Lebo R., Varmus H., Bishop J.M., Pettenati M.J.,
RA   le Beau M.M., Diaz M.O., Rowley J.D.;
RT   "Identification of a human gene (HCK) that encodes a protein-tyrosine
RT   kinase and is expressed in hemopoietic cells.";
RL   Mol. Cell. Biol. 7:2267-2275(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=3453117; DOI=10.1128/MCB.7.6.2276;
RA   Ziegler S.F., Marth J.D., Lewis D.B., Perlmutter R.M.;
RT   "Novel protein-tyrosine kinase gene (hck) preferentially expressed in
RT   cells of hematopoietic origin.";
RL   Mol. Cell. Biol. 7:2276-2285(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 4), AND VARIANT
RP   LEU-105.
RC   TISSUE=Corpus callosum, and Ileal mucosa;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=B-cell, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-21 (ISOFORM 1), AND ALTERNATIVE
RP   INITIATION.
RC   TISSUE=Bone marrow;
RX   PubMed=1875927; DOI=10.1128/MCB.11.9.4363;
RA   Lock P., Ralph S., Stanley E., Boulet I., Ramsay R., Dunn A.R.;
RT   "Two isoforms of murine hck, generated by utilization of alternative
RT   translational initiation codons, exhibit different patterns of
RT   subcellular localization.";
RL   Mol. Cell. Biol. 11:4363-4370(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 178-526.
RC   TISSUE=Spleen;
RX   PubMed=1572549; DOI=10.1016/0378-1119(92)90407-G;
RA   Hradetzky D., Strebhardt K., Ruesamen-Waigmann H.;
RT   "The genomic locus of the human hemopoietic-specific cell protein
RT   tyrosine kinase (PTK)-encoding gene (HCK) confirms conservation of
RT   exon-intron structure among human PTKs of the src family.";
RL   Gene 113:275-280(1992).
RN   [9]
RP   INTERACTION WITH FCGR2A, CATALYTIC ACTIVITY, AND FUNCTION IN
RP   PHOSPHORYLATION OF FCGR2A.
RX   PubMed=8132624;
RA   Ghazizadeh S., Bolen J.B., Fleit H.B.;
RT   "Physical and functional association of Src-related protein tyrosine
RT   kinases with Fc gamma RII in monocytic THP-1 cells.";
RL   J. Biol. Chem. 269:8878-8884(1994).
RN   [10]
RP   INTERACTION WITH FCGR1A, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND
RP   PHOSPHORYLATION.
RX   PubMed=8064233; DOI=10.1084/jem.180.3.1165;
RA   Wang A.V., Scholl P.R., Geha R.S.;
RT   "Physical and functional association of the high affinity
RT   immunoglobulin G receptor (Fc gamma RI) with the kinases Hck and
RT   Lyn.";
RL   J. Exp. Med. 180:1165-1170(1994).
RN   [11]
RP   FUNCTION IN FCGR1A SIGNALING, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION,
RP   AND ENZYME REGULATION.
RX   PubMed=7535819;
RA   Durden D.L., Kim H.M., Calore B., Liu Y.;
RT   "The Fc gamma RI receptor signals through the activation of hck and
RT   MAP kinase.";
RL   J. Immunol. 154:4039-4047(1995).
RN   [12]
RP   SUBCELLULAR LOCATION, ALTERNATIVE INITIATION, MYRISTOYLATION AT GLY-2,
RP   MYRISTOYLATION AT GLY-2 (ISOFORM 2), PALMITOYLATION AT CYS-3 (ISOFORM
RP   2), AND MUTAGENESIS OF GLY-3; GLY-23 AND CYS-24.
RX   PubMed=7791757; DOI=10.1128/MCB.15.7.3507;
RA   Robbins S.M., Quintrell N.A., Bishop J.M.;
RT   "Myristoylation and differential palmitoylation of the HCK protein-
RT   tyrosine kinases govern their attachment to membranes and association
RT   with caveolae.";
RL   Mol. Cell. Biol. 15:3507-3515(1995).
RN   [13]
RP   FUNCTION, ENZYME REGULATION, PHOSPHORYLATION, AND INTERACTION WITH
RP   IL6ST.
RX   PubMed=9406996;
RA   Hallek M., Neumann C., Schaffer M., Danhauser-Riedl S.,
RA   von Bubnoff N., de Vos G., Druker B.J., Yasukawa K., Griffin J.D.,
RA   Emmerich B.;
RT   "Signal transduction of interleukin-6 involves tyrosine
RT   phosphorylation of multiple cytosolic proteins and activation of Src-
RT   family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.";
RL   Exp. Hematol. 25:1367-1377(1997).
RN   [14]
RP   INDUCTION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=8995234; DOI=10.1074/jbc.272.1.102;
RA   Welch H., Maridonneau-Parini I.;
RT   "Hck is activated by opsonized zymosan and A23187 in distinct
RT   subcellular fractions of human granulocytes.";
RL   J. Biol. Chem. 272:102-109(1997).
RN   [15]
RP   ENZYME REGULATION, AND INTERACTION WITH HIV-1 NEF.
RX   PubMed=9218412; DOI=10.1074/jbc.272.29.17899;
RA   Briggs S.D., Sharkey M., Stevenson M., Smithgall T.E.;
RT   "SH3-mediated Hck tyrosine kinase activation and fibroblast
RT   transformation by the Nef protein of HIV-1.";
RL   J. Biol. Chem. 272:17899-17902(1997).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF BCR, AND INTERACTION WITH BCR-ABL.
RX   PubMed=9407116; DOI=10.1074/jbc.272.52.33260;
RA   Warmuth M., Bergmann M., Priess A., Hauslmann K., Emmerich B.,
RA   Hallek M.;
RT   "The Src family kinase Hck interacts with Bcr-Abl by a kinase-
RT   independent mechanism and phosphorylates the Grb2-binding site of
RT   Bcr.";
RL   J. Biol. Chem. 272:33260-33270(1997).
RN   [17]
RP   FUNCTION IN CBL PHOSPHORYLATION; CELL PROLIFERATION AND REGULATION OF
RP   CELL SHAPE, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, MUTAGENESIS OF
RP   TYR-522, AND INTERACTION WITH CBL.
RX   PubMed=10092522; DOI=10.1006/bbrc.1999.0427;
RA   Howlett C.J., Bisson S.A., Resek M.E., Tigley A.W., Robbins S.M.;
RT   "The proto-oncogene p120(Cbl) is a downstream substrate of the Hck
RT   protein-tyrosine kinase.";
RL   Biochem. Biophys. Res. Commun. 257:129-138(1999).
RN   [18]
RP   FUNCTION IN IL2 SIGNALING, CATALYTIC ACTIVITY, INDUCTION, ENZYME
RP   REGULATION, AND PHOSPHORYLATION.
RX   PubMed=10779760; DOI=10.4049/jimmunol.164.9.4575;
RA   Bosco M.C., Curiel R.E., Zea A.H., Malabarba M.G., Ortaldo J.R.,
RA   Espinoza-Delgado I.;
RT   "IL-2 signaling in human monocytes involves the phosphorylation and
RT   activation of p59hck.";
RL   J. Immunol. 164:4575-4585(2000).
RN   [19]
RP   PHOSPHORYLATION AT TYR-411 AND TYR-522, IDENTIFICATION BY MASS
RP   SPECTROMETRY, ENZYME REGULATION, AND MUTAGENESIS OF GLU-305 AND
RP   TYR-411.
RX   PubMed=10644735; DOI=10.1074/jbc.275.4.2721;
RA   Porter M., Schindler T., Kuriyan J., Miller W.T.;
RT   "Reciprocal regulation of Hck activity by phosphorylation of Tyr(527)
RT   and Tyr(416). Effect of introducing a high affinity intramolecular SH2
RT   ligand.";
RL   J. Biol. Chem. 275:2721-2726(2000).
RN   [20]
RP   FUNCTION IN IL8-MEDIATED DEGRANULATION, ENZYME REGULATION, AND
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=10973280; DOI=10.1038/79767;
RA   Barlic J., Andrews J.D., Kelvin A.A., Bosinger S.E., DeVries M.E.,
RA   Xu L., Dobransky T., Feldman R.D., Ferguson S.S., Kelvin D.J.;
RT   "Regulation of tyrosine kinase activation and granule release through
RT   beta-arrestin by CXCRI.";
RL   Nat. Immunol. 1:227-233(2000).
RN   [21]
RP   INTERACTION WITH HIV-1 VIF.
RX   PubMed=11278465; DOI=10.1074/jbc.M009076200;
RA   Hassaine G., Courcoul M., Bessou G., Barthalay Y., Picard C.,
RA   Olive D., Collette Y., Vigne R., Decroly E.;
RT   "The tyrosine kinase Hck is an inhibitor of HIV-1 replication
RT   counteracted by the viral vif protein.";
RL   J. Biol. Chem. 276:16885-16893(2001).
RN   [22]
RP   INTERACTION WITH HEV ORF3 PROTEIN.
RX   PubMed=11518702; DOI=10.1074/jbc.M101546200;
RA   Korkaya H., Jameel S., Gupta D., Tyagi S., Kumar R., Zafrullah M.,
RA   Mazumdar M., Lal S.K., Xiaofang L., Sehgal D., Das S.R., Sahal D.;
RT   "The ORF3 protein of hepatitis E virus binds to Src homology 3 domains
RT   and activates MAPK.";
RL   J. Biol. Chem. 276:42389-42400(2001).
RN   [23]
RP   FUNCTION AS EFFECTOR OF THE BCR-ABL FUSION PROTEIN IN PHOSPHORYLATION
RP   OF STAT5B, INTERACTION WITH STAT5B AND THE BCR-ABL FUSION PROTEIN, AND
RP   PHOSPHORYLATION.
RX   PubMed=12411494; DOI=10.1093/emboj/cdf562;
RA   Klejman A., Schreiner S.J., Nieborowska-Skorska M., Slupianek A.,
RA   Wilson M., Smithgall T.E., Skorski T.;
RT   "The Src family kinase Hck couples BCR/ABL to STAT5 activation in
RT   myeloid leukemia cells.";
RL   EMBO J. 21:5766-5774(2002).
RN   [24]
RP   INTERACTION WITH ADAM15, AND FUNCTION IN PHOSPHORYLATION OF ADAM15.
RX   PubMed=11741929; DOI=10.1074/jbc.M107430200;
RA   Poghosyan Z., Robbins S.M., Houslay M.D., Webster A., Murphy G.,
RA   Edwards D.R.;
RT   "Phosphorylation-dependent interactions between ADAM15 cytoplasmic
RT   domain and Src family protein-tyrosine kinases.";
RL   J. Biol. Chem. 277:4999-5007(2002).
RN   [25]
RP   FUNCTION IN REORGANIZATION OF THE ACTIN CYTOSKELETON; FORMATION OF
RP   CELL PROTRUSIONS AND PHAGOCYTOSIS (ISOFORM 2), SUBCELLULAR LOCATION
RP   (ISOFORM 2), AND MUTAGENESIS OF GLY-3.
RX   PubMed=11904303; DOI=10.1074/jbc.M201212200;
RA   Carreno S., Caron E., Cougoule C., Emorine L.J.,
RA   Maridonneau-Parini I.;
RT   "p59Hck isoform induces F-actin reorganization to form protrusions of
RT   the plasma membrane in a Cdc42- and Rac-dependent manner.";
RL   J. Biol. Chem. 277:21007-21016(2002).
RN   [26]
RP   FUNCTION IN CELL PROLIFERATION, UBIQUITINATION, PHOSPHORYLATION AT
RP   TYR-51; TYR-411 AND TYR-522, SUBCELLULAR LOCATION, INTERACTION WITH
RP   CBL (ISOFORM 2), AND MUTAGENESIS OF LYS-290 AND TYR-522.
RX   PubMed=11896602; DOI=10.1038/sj.onc.1205228;
RA   Howlett C.J., Robbins S.M.;
RT   "Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated
RT   cellular transformation.";
RL   Oncogene 21:1707-1716(2002).
RN   [27]
RP   FUNCTION IN IL6 SIGNALING CASCADE AND IN PHOSPHORYLATION OF GAB1 AND
RP   GAB2.
RX   PubMed=15010462; DOI=10.1074/jbc.M305783200;
RA   Podar K., Mostoslavsky G., Sattler M., Tai Y.T., Hayashi T.,
RA   Catley L.P., Hideshima T., Mulligan R.C., Chauhan D., Anderson K.C.;
RT   "Critical role for hematopoietic cell kinase (Hck)-mediated
RT   phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-
RT   induced proliferation and survival of multiple myeloma cells.";
RL   J. Biol. Chem. 279:21658-21665(2004).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF ELMO1, AND INTERACTION WITH ELMO1.
RX   PubMed=15952790; DOI=10.1021/bi0500832;
RA   Yokoyama N., deBakker C.D., Zappacosta F., Huddleston M.J.,
RA   Annan R.S., Ravichandran K.S., Miller W.T.;
RT   "Identification of tyrosine residues on ELMO1 that are phosphorylated
RT   by the Src-family kinase Hck.";
RL   Biochemistry 44:8841-8849(2005).
RN   [29]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ASP-381.
RX   PubMed=15998323; DOI=10.1111/j.1600-0854.2005.00307.x;
RA   Cougoule C., Carreno S., Castandet J., Labrousse A.,
RA   Astarie-Dequeker C., Poincloux R., Le Cabec V., Maridonneau-Parini I.;
RT   "Activation of the lysosome-associated p61Hck isoform triggers the
RT   biogenesis of podosomes.";
RL   Traffic 6:682-694(2005).
RN   [30]
RP   INTERACTION WITH HIV-1 NEF, AND ENZYME REGULATION.
RX   PubMed=16849330; DOI=10.1074/jbc.M601128200;
RA   Trible R.P., Emert-Sedlak L., Smithgall T.E.;
RT   "HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-
RT   Src through direct SH3 domain interaction.";
RL   J. Biol. Chem. 281:27029-27038(2006).
RN   [31]
RP   FUNCTION IN PHOSPHORYLATION AND INHIBITION OF TP73 ACTIVITY,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH TP73 AND YAP1.
RX   PubMed=17535448; DOI=10.1186/1471-2199-8-45;
RA   Paliwal P., Radha V., Swarup G.;
RT   "Regulation of p73 by Hck through kinase-dependent and independent
RT   mechanisms.";
RL   BMC Mol. Biol. 8:45-45(2007).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH IL6ST.
RX   PubMed=17310994; DOI=10.1038/sj.onc.1210306;
RA   Hausherr A., Tavares R., Schaffer M., Obermeier A., Miksch C.,
RA   Mitina O., Ellwart J., Hallek M., Krause G.;
RT   "Inhibition of IL-6-dependent growth of myeloma cells by an acidic
RT   peptide repressing the gp130-mediated activation of Src family
RT   kinases.";
RL   Oncogene 26:4987-4998(2007).
RN   [33]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL
RT   (CD178) by phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [34]
RP   FUNCTION IN REORGANIZATION OF ACTIN CYTOSKELETON AND CELL
RP   PROLIFERATION, AND ROLE IN DISEASE.
RX   PubMed=19114024; DOI=10.1016/j.ejca.2008.11.020;
RA   Poincloux R., Al Saati T., Maridonneau-Parini I., Le Cabec V.;
RT   "The oncogenic activity of the Src family kinase Hck requires the
RT   cooperative action of the plasma membrane- and lysosome-associated
RT   isoforms.";
RL   Eur. J. Cancer 45:321-327(2009).
RN   [35]
RP   INTERACTION WITH ADAM15.
RX   PubMed=19718658; DOI=10.1002/jcb.22317;
RA   Kleino I., Ortiz R.M., Yritys M., Huovila A.P., Saksela K.;
RT   "Alternative splicing of ADAM15 regulates its interactions with
RT   cellular SH3 proteins.";
RL   J. Cell. Biochem. 108:877-885(2009).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND SER-462, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [37]
RP   FUNCTION IN ABL1-MEDIATED CELL MIGRATION, AND IDENTIFICATION IN A
RP   COMPLEX WITH ITGB1 AND WITH ABL1.
RX   PubMed=19903482; DOI=10.1016/j.febslet.2009.11.009;
RA   Baruzzi A., Iacobucci I., Soverini S., Lowell C.A., Martinelli G.,
RA   Berton G.;
RT   "c-Abl and Src-family kinases cross-talk in regulation of myeloid cell
RT   migration.";
RL   FEBS Lett. 584:15-21(2010).
RN   [38]
RP   ROLE IN DISEASE, AND FUNCTION IN PHOSPHORYLATION OF THE BCR-ABL FUSION
RP   PROTEIN.
RX   PubMed=20452982; DOI=10.1074/jbc.M109.090043;
RA   Pene-Dumitrescu T., Smithgall T.E.;
RT   "Expression of a Src family kinase in chronic myelogenous leukemia
RT   cells induces resistance to imatinib in a kinase-dependent manner.";
RL   J. Biol. Chem. 285:21446-21457(2010).
RN   [39]
RP   REVIEW ON ROLE IN PHAGOCYTOSIS AND SUBSTRATES.
RX   PubMed=18538446; DOI=10.1016/j.ejcb.2008.03.008;
RA   Guiet R., Poincloux R., Castandet J., Marois L., Labrousse A.,
RA   Le Cabec V., Maridonneau-Parini I.;
RT   "Hematopoietic cell kinase (Hck) isoforms and phagocyte duties - from
RT   signaling and actin reorganization to migration and phagocytosis.";
RL   Eur. J. Cell Biol. 87:527-542(2008).
RN   [40]
RP   ROLE IN NEUTROPHIL FUNCTION, AND SIGNALING.
RX   PubMed=21338576; DOI=10.1016/j.abb.2011.02.009;
RA   Zarbock A., Ley K.;
RT   "Protein tyrosine kinases in neutrophil activation and recruitment.";
RL   Arch. Biochem. Biophys. 510:112-119(2011).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-36, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   INTERACTION WITH WDCP.
RX   PubMed=25469238; DOI=10.3892/br.2014.374;
RA   Yokoyama N., Miller W.T.;
RT   "Molecular characterization of WDCP, a novel fusion partner for the
RT   anaplastic lymphoma tyrosine kinase ALK.";
RL   Biomed. Rep. 3:9-13(2015).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [44]
RP   STRUCTURE BY NMR OF 140-245.
RX   PubMed=9109402; DOI=10.1016/S0014-5793(97)00255-X;
RA   Zhang W., Smithgall T.E., Gmeiner W.H.;
RT   "Sequential assignment and secondary structure determination for the
RT   Src homology 2 domain of hematopoietic cellular kinase.";
RL   FEBS Lett. 406:131-135(1997).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 78-526 IN COMPLEX WITH
RP   CALCIUM, AND PHOSPHORYLATION AT TYR-522.
RX   PubMed=9024658; DOI=10.1038/385602a0;
RA   Sicheri F., Moarefi I., Kuriyan J.;
RT   "Crystal structure of the Src family tyrosine kinase Hck.";
RL   Nature 385:602-609(1997).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 81-137.
RX   PubMed=9778343; DOI=10.1021/bi980989q;
RA   Arold S., O'Brien R., Franken P., Strub M.-P., Hoh F., Dumas C.,
RA   Ladbury J.E.;
RT   "RT loop flexibility enhances the specificity of Src family SH3
RT   domains for HIV-1 Nef.";
RL   Biochemistry 37:14683-14691(1998).
RN   [47]
RP   STRUCTURE BY NMR OF 72-143.
RX   PubMed=9571048; DOI=10.1006/jmbi.1998.1690;
RA   Horita D.A., Baldisseri D.M., Zhang W., Altieri A.S., Smithgall T.E.,
RA   Gmeiner W.H., Byrd R.A.;
RT   "Solution structure of the human Hck SH3 domain and identification of
RT   its ligand binding site.";
RL   J. Mol. Biol. 278:253-265(1998).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 81-522 IN COMPLEX WITH THE
RP   PYRAZOLO PYRIMIDINE-TYPE INHIBITOR PP1, AND PHOSPHORYLATION AT
RP   TYR-522.
RX   PubMed=10360180; DOI=10.1016/S1097-2765(00)80357-3;
RA   Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., Kuriyan J.;
RT   "Crystal structure of Hck in complex with a Src family-selective
RT   tyrosine kinase inhibitor.";
RL   Mol. Cell 3:639-648(1999).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 81-522 IN COMPLEXES WITH
RP   INHIBITORS A-420983; A-641359 AND A-770041, ENZYME REGULATION, AND
RP   PHOSPHORYLATION AT TYR-522.
RX   PubMed=16216497; DOI=10.1016/j.bmcl.2005.09.039;
RA   Burchat A., Borhani D.W., Calderwood D.J., Hirst G.C., Li B.,
RA   Stachlewitz R.F.;
RT   "Discovery of A-770041, a src-family selective orally active lck
RT   inhibitor that prevents organ allograft rejection.";
RL   Bioorg. Med. Chem. Lett. 16:118-122(2006).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 247-513 IN COMPLEX WITH
RP   INHIBITOR PG-1009247.
RX   PubMed=16997556; DOI=10.1016/j.bmcl.2006.08.132;
RA   Sabat M., VanRens J.C., Laufersweiler M.J., Brugel T.A., Maier J.,
RA   Golebiowski A., De B., Easwaran V., Hsieh L.C., Walter R.L.,
RA   Mekel M.J., Evdokimov A., Janusz M.J.;
RT   "The development of 2-benzimidazole substituted pyrimidine based
RT   inhibitors of lymphocyte specific kinase (Lck).";
RL   Bioorg. Med. Chem. Lett. 16:5973-5977(2006).
RN   [51]
RP   STRUCTURE BY NMR OF 61-140 IN COMPLEX WITH PROLINE-RICH SYNTHETIC
RP   PEPTIDE.
RX   PubMed=17141806; DOI=10.1016/j.jmb.2006.11.013;
RA   Schmidt H., Hoffmann S., Tran T., Stoldt M., Stangler T., Wiesehan K.,
RA   Willbold D.;
RT   "Solution structure of a Hck SH3 domain ligand complex reveals novel
RT   interaction modes.";
RL   J. Mol. Biol. 365:1517-1532(2007).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.61 ANGSTROMS) OF 72-256, ENZYME REGULATION,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=20810664; DOI=10.1074/jbc.M110.145102;
RA   Alvarado J.J., Betts L., Moroco J.A., Smithgall T.E., Yeh J.I.;
RT   "Crystal structure of the Src family kinase Hck SH3-SH2 linker
RT   regulatory region supports an SH3-dominant activation mechanism.";
RL   J. Biol. Chem. 285:35455-35461(2010).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (3.45 ANGSTROMS) OF 79-138 IN COMPLEX WITH HIV-1
RP   NEF, AND INTERACTION WITH HIV-1 NEF.
RX   PubMed=21625496; DOI=10.1371/journal.pone.0020033;
RA   Breuer S., Schievink S.I., Schulte A., Blankenfeldt W., Fackler O.T.,
RA   Geyer M.;
RT   "Molecular design, functional characterization and structural basis of
RT   a protein inhibitor against the HIV-1 pathogenicity factor Nef.";
RL   PLoS ONE 6:E20033-E20033(2011).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 79-138 IN COMPLEX WITH HIV-1
RP   NEF, AND INTERACTION WITH HIV-1 NEF.
RX   PubMed=21477083; DOI=10.1111/j.1600-0854.2011.01205.x;
RA   Horenkamp F.A., Breuer S., Schulte A., Lulf S., Weyand M., Saksela K.,
RA   Geyer M.;
RT   "Conformation of the dileucine-based sorting motif in HIV-1 Nef
RT   revealed by intermolecular domain assembly.";
RL   Traffic 12:867-877(2011).
RN   [55]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-44; LEU-105 AND GLY-399.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase found in
CC       hematopoietic cells that transmits signals from cell surface
CC       receptors and plays an important role in the regulation of innate
CC       immune responses, including neutrophil, monocyte, macrophage and
CC       mast cell functions, phagocytosis, cell survival and
CC       proliferation, cell adhesion and migration. Acts downstream of
CC       receptors that bind the Fc region of immunoglobulins, such as
CC       FCGR1A and FCGR2A, but also CSF3R, PLAUR, the receptors for IFNG,
CC       IL2, IL6 and IL8, and integrins, such as ITGB1 and ITGB2. During
CC       the phagocytic process, mediates mobilization of secretory
CC       lysosomes, degranulation, and activation of NADPH oxidase to bring
CC       about the respiratory burst. Plays a role in the release of
CC       inflammatory molecules. Promotes reorganization of the actin
CC       cytoskeleton and actin polymerization, formation of podosomes and
CC       cell protrusions. Inhibits TP73-mediated transcription activation
CC       and TP73-mediated apoptosis. Phosphorylates CBL in response to
CC       activation of immunoglobulin gamma Fc region receptors.
CC       Phosphorylates ADAM15, BCR, ELMO1, FCGR2A, GAB1, GAB2, RAPGEF1,
CC       STAT5B, TP73, VAV1 and WAS. {ECO:0000269|PubMed:10092522,
CC       ECO:0000269|PubMed:10779760, ECO:0000269|PubMed:10973280,
CC       ECO:0000269|PubMed:11741929, ECO:0000269|PubMed:11896602,
CC       ECO:0000269|PubMed:12411494, ECO:0000269|PubMed:15010462,
CC       ECO:0000269|PubMed:15952790, ECO:0000269|PubMed:15998323,
CC       ECO:0000269|PubMed:17310994, ECO:0000269|PubMed:17535448,
CC       ECO:0000269|PubMed:19114024, ECO:0000269|PubMed:19903482,
CC       ECO:0000269|PubMed:20452982, ECO:0000269|PubMed:21338576,
CC       ECO:0000269|PubMed:7535819, ECO:0000269|PubMed:8132624,
CC       ECO:0000269|PubMed:9406996, ECO:0000269|PubMed:9407116}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:10092522,
CC       ECO:0000269|PubMed:10779760, ECO:0000269|PubMed:15998323,
CC       ECO:0000269|PubMed:20810664, ECO:0000269|PubMed:7535819,
CC       ECO:0000269|PubMed:8064233, ECO:0000269|PubMed:8132624,
CC       ECO:0000269|PubMed:8995234}.
CC   -!- ENZYME REGULATION: Subject to autoinhibition, mediated by
CC       intramolecular interactions involving the SH2 and SH3 domains.
CC       Kinase activity is also regulated by phosphorylation at regulatory
CC       tyrosine residues. Phosphorylation at Tyr-411 is required for
CC       optimal activity. Phosphorylation at Tyr-522 inhibits kinase
CC       activity. Inhibited by PP1 and A-770041.
CC       {ECO:0000269|PubMed:10644735, ECO:0000269|PubMed:10779760,
CC       ECO:0000269|PubMed:10973280, ECO:0000269|PubMed:16216497,
CC       ECO:0000269|PubMed:16849330, ECO:0000269|PubMed:20810664,
CC       ECO:0000269|PubMed:7535819, ECO:0000269|PubMed:9218412,
CC       ECO:0000269|PubMed:9406996}.
CC   -!- SUBUNIT: Interacts (via SH2 domain) with FLT3 (tyrosine
CC       phosphorylated). Interacts with VAV1, WAS and RAPGEF1 (By
CC       similarity). Interacts (via SH3 domain) with HIV-1 Nef and Vif.
CC       This interaction stimulates its tyrosine-kinase activity.
CC       Interacts (via SH3 domain) with HEV ORF3 protein. Interacts with
CC       ARRB1 and ARRB2. Interacts with ADAM15. Interacts with FASLG.
CC       Interacts with CBL. Interacts with FCGR1A; the interaction may be
CC       indirect. Interacts with IL6ST. Interacts (via SH3 domain) with
CC       ELMO1. Interacts (via SH3 domain) with TP73. Interacts with YAP1.
CC       Interacts with ABL1 and ITGB1, and thereby recruits ABL1 to
CC       activated ITGB1. Interacts (via SH3 domain) with WDCP.
CC       {ECO:0000250, ECO:0000269|PubMed:10092522,
CC       ECO:0000269|PubMed:10360180, ECO:0000269|PubMed:10973280,
CC       ECO:0000269|PubMed:11278465, ECO:0000269|PubMed:11518702,
CC       ECO:0000269|PubMed:11741929, ECO:0000269|PubMed:12411494,
CC       ECO:0000269|PubMed:15952790, ECO:0000269|PubMed:16849330,
CC       ECO:0000269|PubMed:16997556, ECO:0000269|PubMed:17141806,
CC       ECO:0000269|PubMed:17310994, ECO:0000269|PubMed:17535448,
CC       ECO:0000269|PubMed:19718658, ECO:0000269|PubMed:19807924,
CC       ECO:0000269|PubMed:19903482, ECO:0000269|PubMed:21477083,
CC       ECO:0000269|PubMed:21625496, ECO:0000269|PubMed:25469238,
CC       ECO:0000269|PubMed:8064233, ECO:0000269|PubMed:8132624,
CC       ECO:0000269|PubMed:9024658, ECO:0000269|PubMed:9218412,
CC       ECO:0000269|PubMed:9406996, ECO:0000269|PubMed:9407116}.
CC   -!- INTERACTION:
CC       O92972:- (xeno); NbExp=2; IntAct=EBI-346340, EBI-710506;
CC       P27958:- (xeno); NbExp=5; IntAct=EBI-346340, EBI-706378;
CC       Q13444:ADAM15; NbExp=3; IntAct=EBI-346340, EBI-77818;
CC       P09917:ALOX5; NbExp=2; IntAct=EBI-346340, EBI-79934;
CC       Q9ULH1:ASAP1; NbExp=2; IntAct=EBI-346340, EBI-346622;
CC       P22681:CBL; NbExp=2; IntAct=EBI-9834454, EBI-518228;
CC       P00533:EGFR; NbExp=2; IntAct=EBI-346340, EBI-297353;
CC       Q92556:ELMO1; NbExp=4; IntAct=EBI-346340, EBI-346417;
CC       P21860:ERBB3; NbExp=2; IntAct=EBI-346340, EBI-720706;
CC       P17948:FLT1; NbExp=2; IntAct=EBI-346340, EBI-1026718;
CC       O43559:FRS3; NbExp=2; IntAct=EBI-9834454, EBI-725515;
CC       Q9HD26:GOPC; NbExp=3; IntAct=EBI-346340, EBI-349832;
CC       Q07666:KHDRBS1; NbExp=4; IntAct=EBI-346340, EBI-1364;
CC       P10721:KIT; NbExp=2; IntAct=EBI-346340, EBI-1379503;
CC       Q6A162:KRT40; NbExp=3; IntAct=EBI-346340, EBI-10171697;
CC       P60411:KRTAP10-9; NbExp=3; IntAct=EBI-346340, EBI-10172052;
CC       Q5JR59:MTUS2; NbExp=3; IntAct=EBI-346340, EBI-742948;
CC       Q90VU7:nef (xeno); NbExp=2; IntAct=EBI-346340, EBI-7460704;
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-346340, EBI-945833;
CC       Q8TAK6:OLIG1; NbExp=2; IntAct=EBI-9834454, EBI-3867416;
CC       Q13177:PAK2; NbExp=2; IntAct=EBI-346340, EBI-1045887;
CC       Q8WUM4:PDCD6IP; NbExp=4; IntAct=EBI-346340, EBI-310624;
CC       P42338:PIK3CB; NbExp=2; IntAct=EBI-346340, EBI-2609540;
CC       Q92569:PIK3R3; NbExp=4; IntAct=EBI-9834454, EBI-79893;
CC       P19174:PLCG1; NbExp=2; IntAct=EBI-346340, EBI-79387;
CC       Q05397:PTK2; NbExp=2; IntAct=EBI-9834454, EBI-702142;
CC       Q07889:SOS1; NbExp=4; IntAct=EBI-346340, EBI-297487;
CC       P12504:vif (xeno); NbExp=3; IntAct=EBI-346340, EBI-779991;
CC       P42768:WAS; NbExp=9; IntAct=EBI-346340, EBI-346375;
CC       O43516:WIPF1; NbExp=3; IntAct=EBI-346340, EBI-346356;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Lysosome. Membrane; Lipid-anchor.
CC       Cell projection, podosome membrane; Lipid-anchor. Cytoplasm,
CC       cytosol. Note=Associated with specialized secretory lysosomes
CC       called azurophil granules. At least half of this isoform is found
CC       in the cytoplasm, some of this fraction is myristoylated.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane
CC       {ECO:0000269|PubMed:11904303}; Lipid-anchor
CC       {ECO:0000269|PubMed:11904303}. Membrane, caveola
CC       {ECO:0000269|PubMed:11904303}; Lipid-anchor
CC       {ECO:0000269|PubMed:11904303}. Cell junction, focal adhesion
CC       {ECO:0000269|PubMed:11904303}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:11904303}. Golgi apparatus
CC       {ECO:0000269|PubMed:11904303}. Cytoplasmic vesicle
CC       {ECO:0000269|PubMed:11904303}. Lysosome
CC       {ECO:0000269|PubMed:11904303}. Nucleus
CC       {ECO:0000269|PubMed:11904303}. Note=20% of this isoform is
CC       associated with caveolae. Localization at the cell membrane and at
CC       caveolae requires palmitoylation at Cys-3. Colocalizes with the
CC       actin cytoskeleton at focal adhesions.
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle.
CC       Cytoplasm, cytosol.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=4;
CC       Name=1; Synonyms=p60-HCK, p61Hck;
CC         IsoId=P08631-1; Sequence=Displayed;
CC         Note=Initiates from a CTG codon.;
CC       Name=2; Synonyms=p59-HCK, p59Hck;
CC         IsoId=P08631-2; Sequence=VSP_018858;
CC         Note=Initiator Met-1 is removed. Contains a N-myristoyl glycine
CC         at position 2. Contains a S-palmitoyl cysteine at position 3.
CC         {ECO:0000269|PubMed:7791757};
CC       Name=3;
CC         IsoId=P08631-3; Sequence=VSP_018858, VSP_041926;
CC       Name=4;
CC         IsoId=P08631-4; Sequence=VSP_041926;
CC         Note=Initiates from a CTG codon.;
CC   -!- TISSUE SPECIFICITY: Detected in monocytes and neutrophils (at
CC       protein level). Expressed predominantly in cells of the myeloid
CC       and B-lymphoid lineages. Highly expressed in granulocytes.
CC       Detected in tonsil. {ECO:0000269|PubMed:3453117,
CC       ECO:0000269|PubMed:8064233, ECO:0000269|PubMed:8995234}.
CC   -!- INDUCTION: Up-regulated during myeloid cell differentiation. The
CC       highest levels are detected in fully differentiated phagocytes.
CC       Up-regulated by IL2. {ECO:0000269|PubMed:10779760,
CC       ECO:0000269|PubMed:8995234}.
CC   -!- DOMAIN: The SH3 domain mediates binding to HIV-1 Nef.
CC   -!- PTM: Phosphorylated on several tyrosine residues.
CC       Autophosphorylated. Becomes rapidly phosphorylated upon activation
CC       of the immunoglobulin receptors FCGR1A and FCGR2A. Phosphorylation
CC       by the BCR-ABL fusion protein mediates activation of HCK.
CC       Phosphorylation at Tyr-411 increases kinase activity.
CC       Phosphorylation at Tyr-522 inhibits kinase activity. Kinase
CC       activity is not required for phosphorylation at Tyr-522,
CC       suggesting that this site is a target of other kinases.
CC       {ECO:0000269|PubMed:10360180, ECO:0000269|PubMed:10644735,
CC       ECO:0000269|PubMed:10779760, ECO:0000269|PubMed:11896602,
CC       ECO:0000269|PubMed:12411494, ECO:0000269|PubMed:16216497,
CC       ECO:0000269|PubMed:8064233, ECO:0000269|PubMed:9024658,
CC       ECO:0000269|PubMed:9406996}.
CC   -!- PTM: Ubiquitinated by CBL, leading to its degradation via the
CC       proteasome. {ECO:0000269|PubMed:11896602}.
CC   -!- PTM: Isoform 2 palmitoylation at position 2 requires prior
CC       myristoylation. Palmitoylation at position 3 is required for
CC       caveolar localization of isoform 2. {ECO:0000269|PubMed:7791757}.
CC   -!- DISEASE: Note=Aberrant activation of HCK by HIV-1 protein Nef
CC       enhances HIV-1 replication and contributes to HIV-1 pathogenicity.
CC   -!- DISEASE: Note=Aberrant activation of HCK, e.g. by the BCR-ABL
CC       fusion protein, promotes cancer cell proliferation.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA52643.1; Type=Frameshift; Positions=20; Evidence={ECO:0000305};
CC       Sequence=BAF82585.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16591; AAA52643.1; ALT_FRAME; mRNA.
DR   EMBL; M16592; AAA52644.1; -; mRNA.
DR   EMBL; AK026432; BAB15482.1; -; mRNA.
DR   EMBL; AK289896; BAF82585.1; ALT_INIT; mRNA.
DR   EMBL; AK298726; BAG60878.1; -; mRNA.
DR   EMBL; AL353092; CAI19694.1; -; Genomic_DNA.
DR   EMBL; AL049539; CAI19694.1; JOINED; Genomic_DNA.
DR   EMBL; AL353092; CAI19695.1; -; Genomic_DNA.
DR   EMBL; AL049539; CAI19695.1; JOINED; Genomic_DNA.
DR   EMBL; AL049539; CAI22966.1; -; Genomic_DNA.
DR   EMBL; AL353092; CAI22966.1; JOINED; Genomic_DNA.
DR   EMBL; AL049539; CAI22967.1; -; Genomic_DNA.
DR   EMBL; AL353092; CAI22967.1; JOINED; Genomic_DNA.
DR   EMBL; CH471077; EAW76392.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76393.1; -; Genomic_DNA.
DR   EMBL; BC014435; AAH14435.2; -; mRNA.
DR   EMBL; BC094847; AAH94847.2; -; mRNA.
DR   EMBL; BC108930; AAI08931.2; -; mRNA.
DR   EMBL; BC108931; AAI08932.2; -; mRNA.
DR   EMBL; BC113854; AAI13855.2; -; mRNA.
DR   EMBL; BC114463; AAI14464.2; -; mRNA.
DR   EMBL; X58741; CAA41565.2; -; Genomic_DNA.
DR   EMBL; X58742; CAA41565.2; JOINED; Genomic_DNA.
DR   EMBL; X58743; CAA41565.2; JOINED; Genomic_DNA.
DR   CCDS; CCDS33460.1; -. [P08631-1]
DR   CCDS; CCDS54453.1; -. [P08631-4]
DR   CCDS; CCDS54455.1; -. [P08631-2]
DR   CCDS; CCDS54456.1; -. [P08631-3]
DR   PIR; A27811; TVHUHC.
DR   PIR; A41263; A41263.
DR   RefSeq; NP_001165600.1; NM_001172129.1. [P08631-2]
DR   RefSeq; NP_001165601.1; NM_001172130.1. [P08631-4]
DR   RefSeq; NP_001165602.1; NM_001172131.1. [P08631-3]
DR   RefSeq; NP_001165604.1; NM_001172133.1. [P08631-2]
DR   RefSeq; NP_002101.2; NM_002110.3. [P08631-1]
DR   UniGene; Hs.655210; -.
DR   PDB; 1AD5; X-ray; 2.60 A; A/B=79-526.
DR   PDB; 1BU1; X-ray; 2.60 A; A/B/C/D/E/F=81-137.
DR   PDB; 1QCF; X-ray; 2.00 A; A=81-526.
DR   PDB; 2C0I; X-ray; 2.30 A; A/B=81-526.
DR   PDB; 2C0O; X-ray; 2.85 A; A/B=81-526.
DR   PDB; 2C0T; X-ray; 2.15 A; A/B=81-526.
DR   PDB; 2HCK; X-ray; 3.00 A; A/B=79-526.
DR   PDB; 2HK5; X-ray; 2.00 A; A=247-514.
DR   PDB; 2OI3; NMR; -; A=61-141.
DR   PDB; 2OJ2; NMR; -; A=61-141.
DR   PDB; 3HCK; NMR; -; A=140-245.
DR   PDB; 3NHN; X-ray; 2.61 A; A=72-256.
DR   PDB; 3RBB; X-ray; 2.35 A; B/D=79-138.
DR   PDB; 3REA; X-ray; 2.00 A; B/D=79-138.
DR   PDB; 3REB; X-ray; 3.45 A; B/D=79-138.
DR   PDB; 3VRY; X-ray; 2.48 A; A/B=81-526.
DR   PDB; 3VRZ; X-ray; 2.22 A; A/B=81-526.
DR   PDB; 3VS0; X-ray; 2.93 A; A/B=81-526.
DR   PDB; 3VS1; X-ray; 2.46 A; A/B=81-526.
DR   PDB; 3VS2; X-ray; 2.61 A; A/B=81-526.
DR   PDB; 3VS3; X-ray; 2.17 A; A/B=81-526.
DR   PDB; 3VS4; X-ray; 2.75 A; A/B=81-526.
DR   PDB; 3VS5; X-ray; 2.85 A; A/B=81-526.
DR   PDB; 3VS6; X-ray; 2.37 A; A/B=81-526.
DR   PDB; 3VS7; X-ray; 3.00 A; A/B=81-526.
DR   PDB; 4HCK; NMR; -; A=72-143.
DR   PDB; 4LUD; X-ray; 2.85 A; A/B=81-526.
DR   PDB; 4LUE; X-ray; 3.04 A; A/B=81-526.
DR   PDB; 4ORZ; X-ray; 2.00 A; A=77-138.
DR   PDB; 4U5W; X-ray; 1.86 A; B/D=72-242.
DR   PDB; 5HCK; NMR; -; A=72-143.
DR   PDBsum; 1AD5; -.
DR   PDBsum; 1BU1; -.
DR   PDBsum; 1QCF; -.
DR   PDBsum; 2C0I; -.
DR   PDBsum; 2C0O; -.
DR   PDBsum; 2C0T; -.
DR   PDBsum; 2HCK; -.
DR   PDBsum; 2HK5; -.
DR   PDBsum; 2OI3; -.
DR   PDBsum; 2OJ2; -.
DR   PDBsum; 3HCK; -.
DR   PDBsum; 3NHN; -.
DR   PDBsum; 3RBB; -.
DR   PDBsum; 3REA; -.
DR   PDBsum; 3REB; -.
DR   PDBsum; 3VRY; -.
DR   PDBsum; 3VRZ; -.
DR   PDBsum; 3VS0; -.
DR   PDBsum; 3VS1; -.
DR   PDBsum; 3VS2; -.
DR   PDBsum; 3VS3; -.
DR   PDBsum; 3VS4; -.
DR   PDBsum; 3VS5; -.
DR   PDBsum; 3VS6; -.
DR   PDBsum; 3VS7; -.
DR   PDBsum; 4HCK; -.
DR   PDBsum; 4LUD; -.
DR   PDBsum; 4LUE; -.
DR   PDBsum; 4ORZ; -.
DR   PDBsum; 4U5W; -.
DR   PDBsum; 5HCK; -.
DR   ProteinModelPortal; P08631; -.
DR   SMR; P08631; -.
DR   BioGrid; 109305; 62.
DR   DIP; DIP-1051N; -.
DR   IntAct; P08631; 97.
DR   MINT; MINT-135300; -.
DR   STRING; 9606.ENSP00000365012; -.
DR   BindingDB; P08631; -.
DR   ChEMBL; CHEMBL3234; -.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB01962; Phosphonotyrosine.
DR   DrugBank; DB04216; Quercetin.
DR   GuidetoPHARMACOLOGY; 2032; -.
DR   iPTMnet; P08631; -.
DR   PhosphoSitePlus; P08631; -.
DR   SwissPalm; P08631; -.
DR   BioMuta; HCK; -.
DR   DMDM; 20141296; -.
DR   MaxQB; P08631; -.
DR   PaxDb; P08631; -.
DR   PeptideAtlas; P08631; -.
DR   PRIDE; P08631; -.
DR   DNASU; 3055; -.
DR   Ensembl; ENST00000518730; ENSP00000427757; ENSG00000101336. [P08631-3]
DR   Ensembl; ENST00000520553; ENSP00000429848; ENSG00000101336. [P08631-2]
DR   Ensembl; ENST00000538448; ENSP00000441169; ENSG00000101336. [P08631-2]
DR   Ensembl; ENST00000629881; ENSP00000486627; ENSG00000101336. [P08631-2]
DR   GeneID; 3055; -.
DR   KEGG; hsa:3055; -.
DR   UCSC; uc002wxi.4; human. [P08631-1]
DR   CTD; 3055; -.
DR   DisGeNET; 3055; -.
DR   GeneCards; HCK; -.
DR   HGNC; HGNC:4840; HCK.
DR   HPA; CAB005195; -.
DR   HPA; HPA063768; -.
DR   MIM; 142370; gene.
DR   neXtProt; NX_P08631; -.
DR   OpenTargets; ENSG00000101336; -.
DR   PharmGKB; PA29216; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOGENOM; HOG000233858; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P08631; -.
DR   KO; K08893; -.
DR   PhylomeDB; P08631; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-164944; Nef and signal transduction.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   SignaLink; P08631; -.
DR   SIGNOR; P08631; -.
DR   ChiTaRS; HCK; human.
DR   EvolutionaryTrace; P08631; -.
DR   GeneWiki; HCK; -.
DR   GenomeRNAi; 3055; -.
DR   PRO; PR:P08631; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000101336; -.
DR   ExpressionAtlas; P08631; baseline and differential.
DR   Genevisible; P08631; HS.
DR   GO; GO:0005901; C:caveola; IDA:UniProtKB.
DR   GO; GO:0042995; C:cell projection; IEA:UniProtKB-KW.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IMP:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0030133; C:transport vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0001784; F:phosphotyrosine binding; IPI:CAFA.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; TAS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:UniProtKB.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0002758; P:innate immune response-activating signal transduction; TAS:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; TAS:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:UniProtKB.
DR   GO; GO:0043299; P:leukocyte degranulation; TAS:UniProtKB.
DR   GO; GO:0002522; P:leukocyte migration involved in immune response; TAS:UniProtKB.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; TAS:UniProtKB.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IMP:UniProtKB.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; TAS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0050690; P:regulation of defense response to virus by virus; TAS:Reactome.
DR   GO; GO:0050727; P:regulation of inflammatory response; TAS:UniProtKB.
DR   GO; GO:0050764; P:regulation of phagocytosis; IMP:UniProtKB.
DR   GO; GO:0071801; P:regulation of podosome assembly; IDA:UniProtKB.
DR   GO; GO:0051090; P:regulation of sequence-specific DNA binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0045728; P:respiratory burst after phagocytosis; TAS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing;
KW   ATP-binding; Cell junction; Cell membrane; Cell projection;
KW   Complete proteome; Cytoplasm; Cytoplasmic vesicle; Cytoskeleton;
KW   Exocytosis; Golgi apparatus; Host-virus interaction; Immunity;
KW   Inflammatory response; Innate immunity; Kinase; Lipoprotein; Lysosome;
KW   Membrane; Myristate; Nucleotide-binding; Nucleus; Palmitate;
KW   Phagocytosis; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    526       Tyrosine-protein kinase HCK.
FT                                /FTId=PRO_0000024433.
FT   DOMAIN       78    138       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      144    241       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      262    515       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     268    276       ATP.
FT   ACT_SITE    381    381       Proton acceptor.
FT   BINDING     290    290       ATP.
FT   MOD_RES      36     36       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      51     51       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11896602}.
FT   MOD_RES     202    202       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     209    209       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P08103}.
FT   MOD_RES     411    411       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10644735,
FT                                ECO:0000269|PubMed:11896602}.
FT   MOD_RES     462    462       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     522    522       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:10360180,
FT                                ECO:0000269|PubMed:10644735,
FT                                ECO:0000269|PubMed:11896602,
FT                                ECO:0000269|PubMed:16216497,
FT                                ECO:0000269|PubMed:9024658}.
FT   LIPID         2      2       N-myristoyl glycine.
FT                                {ECO:0000269|PubMed:7791757}.
FT   VAR_SEQ       1     21       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:3453117}.
FT                                /FTId=VSP_018858.
FT   VAR_SEQ      76     76       Missing (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041926.
FT   VARIANT      44     44       A -> T (in dbSNP:rs56029200).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041707.
FT   VARIANT     105    105       M -> L (in dbSNP:rs55722810).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041708.
FT   VARIANT     399    399       D -> G (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041709.
FT   VARIANT     502    502       P -> Q (in dbSNP:rs17093828).
FT                                /FTId=VAR_033836.
FT   MUTAGEN       3      3       G->C: Slight palmitoylation, cytoplasmic
FT                                and caveolar localization; in isoform 1;.
FT                                {ECO:0000269|PubMed:11904303,
FT                                ECO:0000269|PubMed:7791757}.
FT   MUTAGEN       3      3       G->S: Abolishes palmitoylation and
FT                                localization at the cell membrane.
FT                                {ECO:0000269|PubMed:11904303,
FT                                ECO:0000269|PubMed:7791757}.
FT   MUTAGEN      23     23       G->A: Myristoylation and palmitoylation
FT                                are abolished, leading to entirely
FT                                cytoplasmic localization; in isoform 2.
FT                                {ECO:0000269|PubMed:7791757}.
FT   MUTAGEN      24     24       C->S: Palmitoylation is abolished, some
FT                                cytoplasmic and no calveolar
FT                                localization; in isoform 2.
FT                                {ECO:0000269|PubMed:7791757}.
FT   MUTAGEN     290    290       K->E: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:11896602}.
FT   MUTAGEN     305    305       E->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:10644735}.
FT   MUTAGEN     381    381       D->E: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15998323}.
FT   MUTAGEN     411    411       Y->A: Reduced catalytic activity and
FT                                higher affinity for target peptides.
FT                                {ECO:0000269|PubMed:10644735}.
FT   MUTAGEN     522    522       Y->F: Constitutively activated kinase,
FT                                leading to cellular transformation.
FT                                {ECO:0000269|PubMed:10092522,
FT                                ECO:0000269|PubMed:11896602}.
FT   CONFLICT     24     24       C -> S (in Ref. 1; AAA52643).
FT                                {ECO:0000305}.
FT   CONFLICT     69     69       N -> D (in Ref. 3; BAF82585).
FT                                {ECO:0000305}.
FT   CONFLICT    144    144       W -> R (in Ref. 3; BAB15482).
FT                                {ECO:0000305}.
FT   CONFLICT    168    168       F -> Y (in Ref. 3; BAF82585).
FT                                {ECO:0000305}.
FT   CONFLICT    378    378       I -> T (in Ref. 6; AAI13855).
FT                                {ECO:0000305}.
FT   CONFLICT    488    488       N -> S (in Ref. 3; BAF82585).
FT                                {ECO:0000305}.
FT   STRAND       81     87       {ECO:0000244|PDB:4U5W}.
FT   STRAND       93     96       {ECO:0000244|PDB:2C0T}.
FT   STRAND      104    109       {ECO:0000244|PDB:4U5W}.
FT   STRAND      114    119       {ECO:0000244|PDB:4U5W}.
FT   TURN        120    122       {ECO:0000244|PDB:4U5W}.
FT   STRAND      125    129       {ECO:0000244|PDB:4U5W}.
FT   HELIX       130    132       {ECO:0000244|PDB:4U5W}.
FT   STRAND      133    135       {ECO:0000244|PDB:4U5W}.
FT   HELIX       136    138       {ECO:0000244|PDB:2OI3}.
FT   HELIX       139    141       {ECO:0000244|PDB:4U5W}.
FT   STRAND      145    148       {ECO:0000244|PDB:3VS2}.
FT   HELIX       151    159       {ECO:0000244|PDB:4U5W}.
FT   STRAND      168    172       {ECO:0000244|PDB:4U5W}.
FT   STRAND      174    176       {ECO:0000244|PDB:4U5W}.
FT   STRAND      180    188       {ECO:0000244|PDB:4U5W}.
FT   TURN        189    191       {ECO:0000244|PDB:4U5W}.
FT   STRAND      192    202       {ECO:0000244|PDB:4U5W}.
FT   STRAND      204    206       {ECO:0000244|PDB:4U5W}.
FT   STRAND      208    211       {ECO:0000244|PDB:4U5W}.
FT   STRAND      214    218       {ECO:0000244|PDB:4U5W}.
FT   HELIX       219    228       {ECO:0000244|PDB:4U5W}.
FT   STRAND      233    235       {ECO:0000244|PDB:4U5W}.
FT   TURN        252    255       {ECO:0000244|PDB:2HCK}.
FT   HELIX       259    261       {ECO:0000244|PDB:1QCF}.
FT   STRAND      262    269       {ECO:0000244|PDB:1QCF}.
FT   STRAND      272    281       {ECO:0000244|PDB:1QCF}.
FT   TURN        282    284       {ECO:0000244|PDB:1QCF}.
FT   STRAND      285    292       {ECO:0000244|PDB:1QCF}.
FT   STRAND      294    297       {ECO:0000244|PDB:3VS3}.
FT   HELIX       299    309       {ECO:0000244|PDB:1QCF}.
FT   STRAND      320    324       {ECO:0000244|PDB:1QCF}.
FT   STRAND      326    328       {ECO:0000244|PDB:1QCF}.
FT   STRAND      330    333       {ECO:0000244|PDB:1QCF}.
FT   HELIX       341    346       {ECO:0000244|PDB:1QCF}.
FT   HELIX       348    351       {ECO:0000244|PDB:1QCF}.
FT   HELIX       355    374       {ECO:0000244|PDB:1QCF}.
FT   HELIX       384    386       {ECO:0000244|PDB:1QCF}.
FT   STRAND      387    389       {ECO:0000244|PDB:1QCF}.
FT   STRAND      395    397       {ECO:0000244|PDB:1QCF}.
FT   HELIX       402    405       {ECO:0000244|PDB:1QCF}.
FT   HELIX       409    412       {ECO:0000244|PDB:1QCF}.
FT   STRAND      416    419       {ECO:0000244|PDB:1QCF}.
FT   HELIX       421    423       {ECO:0000244|PDB:1QCF}.
FT   HELIX       426    431       {ECO:0000244|PDB:1QCF}.
FT   HELIX       436    451       {ECO:0000244|PDB:1QCF}.
FT   TURN        452    454       {ECO:0000244|PDB:2HK5}.
FT   STRAND      457    460       {ECO:0000244|PDB:1AD5}.
FT   HELIX       463    472       {ECO:0000244|PDB:1QCF}.
FT   STRAND      480    482       {ECO:0000244|PDB:3VS6}.
FT   HELIX       484    493       {ECO:0000244|PDB:1QCF}.
FT   HELIX       498    500       {ECO:0000244|PDB:1QCF}.
FT   HELIX       504    512       {ECO:0000244|PDB:1QCF}.
FT   STRAND      514    518       {ECO:0000244|PDB:1QCF}.
FT   STRAND      521    523       {ECO:0000244|PDB:1QCF}.
SQ   SEQUENCE   526 AA;  59600 MW;  847E877A0A641725 CRC64;
     MGGRSSCEDP GCPRDEERAP RMGCMKSKFL QVGGNTFSKT ETSASPHCPV YVPDPTSTIK
     PGPNSHNSNT PGIREAGSED IIVVALYDYE AIHHEDLSFQ KGDQMVVLEE SGEWWKARSL
     ATRKEGYIPS NYVARVDSLE TEEWFFKGIS RKDAERQLLA PGNMLGSFMI RDSETTKGSY
     SLSVRDYDPR QGDTVKHYKI RTLDNGGFYI SPRSTFSTLQ ELVDHYKKGN DGLCQKLSVP
     CMSSKPQKPW EKDAWEIPRE SLKLEKKLGA GQFGEVWMAT YNKHTKVAVK TMKPGSMSVE
     AFLAEANVMK TLQHDKLVKL HAVVTKEPIY IITEFMAKGS LLDFLKSDEG SKQPLPKLID
     FSAQIAEGMA FIEQRNYIHR DLRAANILVS ASLVCKIADF GLARVIEDNE YTAREGAKFP
     IKWTAPEAIN FGSFTIKSDV WSFGILLMEI VTYGRIPYPG MSNPEVIRAL ERGYRMPRPE
     NCPEELYNIM MRCWKNRPEE RPTFEYIQSV LDDFYTATES QYQQQP
//
